US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Fractyl Health, Inc. - Common Stock (NQ:GUTS)

0.9915 +0.1015 (+11.40%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fractyl Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 3, 2025 ↗
 
Via Benzinga
News headline image
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
What's going on in today's pre-market session ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Participate in the Upcoming December Conferences
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Participate in Upcoming September Investor Conferences
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
GUTS Stock Earnings: Fractyl Health Beats EPS for Q2 2024 ↗
GUTS stock results show that Fractyl Health beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Company will discuss recent corporate updates, including compelling preclinical data from Rejuva® pancreatic gene therapy platform, which was named top abstract at American Diabetes Association’s 84th... 
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s
From Fractyl Health, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >